Diagnosis and management of community-associated MRSA infections in children

References

• Jevons M. ‘Celbenin’-resistant staphylococci. Br. Med. J.1, 124–125 (1961).
   Web of Science ®Google Scholar
• Barrett FF, McGehee RF Jr, Finland M. Methicillin-resistant Staphylococcus aureus at Boston City hospital. Bacteriologic and epidemiologic observations. N. Engl. J. Med.279, 441–448 (1968).
   PubMed Web of Science ®Google Scholar
• Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis.7(2), 178–182 (2001).
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Markowitz N, Arking L, Pohlod D, Fisher E. Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. Ann. Intern. Med.96, 11–16 (1982).
   PubMed Web of Science ®Google Scholar
• Herold BC, Immergluck LC, Maranan MC et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA279, 593–598 (1998).
   PubMed Web of Science ®Google Scholar
• CDC. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus – Minnesota and North Dakota, 1997–1999. Morb. Mortal. Wkly Rep.48, 707–710 (1999).
   PubMedGoogle Scholar
• Mishaan AM, Mason EO Jr, Martinez-Aguilar G et al. Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas. Pediatr. Infect. Dis. J.24(3), 201–206 (2005).
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Hulten KG, Gonzalez BE et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin. Infect. Dis.40(12), 1785–1791 (2005).
   PubMed Web of Science ®Google Scholar
• Ochoa TJ, Mohr J, Wanger A, Murphy JR, Heresi GP. Community-associated methicillin-resistant Staphylococcus aureus in pediatric patients. Emerg. Infect. Dis.11(6), 966–968 (2005).
   PubMed Web of Science ®Google Scholar
• Suggs AH, Maranan MC, Boyle-Vavra S, Daum RS. Methicillin-resistant and borderline methicillin-resistant asymptomatic Staphylococcus aureus colonization in children without identifiable risk factors. Pediatr. Infect. Dis. J.18, 410–414 (1999).
   PubMed Web of Science ®Google Scholar
• Campbell KM, Vaughn AF, Russell KL et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus infections in an outbreak of disease among military trainees in San Diego, California, in 2002. J. Clin. Microbiol.42, 4050–4053 (2004).
   PubMed Web of Science ®Google Scholar
• CDC. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison – Mississippi, 2000. Morb. Mortal. Wkly Rep.50, 919–922 (2001).
   PubMedGoogle Scholar
• Begier EM, Frenette K, Barrett NL et al. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin. Infect. Dis.39, 1446–1453 (2004).
   PubMed Web of Science ®Google Scholar
• CDC. Methicillin-resistant Staphylococcus aureus infections among competitive sports participants – Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000–2003. Morb. Mortal. Wkly Rep.52, 793–795 (2003).
   PubMedGoogle Scholar
• Chambers HF, Hartman BJ, Tomasz A. Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin. J. Clin. Invest.76, 325–331 (1985).
   PubMed Web of Science ®Google Scholar
• Fitzgerald JR, Sturdevant DE, Mackie SM, et al. Evolutionary genomics of Staphylococcus aureus: insights into the origin of methicillin-resistant strains and the toxic shock syndrome epidemic. Proc. Natl Acad. Sci. USA98, 8821–8826 (2001).
   PubMed Web of Science ®Google Scholar
• Enright MC, Robinson DA, Randle G et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc. Natl Acad. Sci. USA99, 7687–7692 (2002).
   PubMed Web of Science ®Google Scholar
• Seybold U, Kourbatova EV, Johnson JG et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin. Infect. Dis.42(5), 647–656 (2006).
   PubMed Web of Science ®Google Scholar
• Voyich JM, Braughton KR, Sturdevant DE et al. Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J. Immunol.175(6), 3907–3919 (2005).
   PubMed Web of Science ®Google Scholar
• Otter JA, French GL. The emergence of community-associated methicillin resistant Staphylococcus aureus at a London teaching hospital, 2000–2006. Clin. Microbiol. Infect.14, 670–676 (2008).
   PubMed Web of Science ®Google Scholar
• Gonzalez EB, Martinez-Aguilar G, Hulten KG. Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics115(3), 642–648
   Google Scholar
• Prevost GP, Couppie P, Prevost S et al. Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J. Med. Microbiol.42, 237–245 (1995).
   PubMed Web of Science ®Google Scholar
• Gillet Y, Issartel B, Vanhems P et al. Association between Staphylococcus aureus strains carrying gene for Panton–Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet359, 753–759 (2002).
   PubMed Web of Science ®Google Scholar
• Martínez-Aguilar G, Avalos-Mishaan A, Hulten K, Hammerman W, Mason EO Jr, Kaplan SL. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr. Infect. Dis. J.23(8), 701–706 (2004).
   PubMed Web of Science ®Google Scholar
• Bocchini CE, Hulten KG, Mason EO Jr et al. Panton–Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics117, 433–440 (2006).
   PubMed Web of Science ®Google Scholar
• Voyich JM, Otto M, Mathema B et al. Is Panton–Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J. Infect. Dis.194, 1761–1770 (2006).
   PubMed Web of Science ®Google Scholar
• Bubeck Wardenburg J, Palazzolo-Balance AM, Otto M, Schneewind O, DeLeo FR. Panton–Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J. Infect. Dis.198(8), 1166–1170 (2008).
   PubMed Web of Science ®Google Scholar
• Montgomery CP, Daum RS. Transcription of inflammatory genes in the lung after infection with community-associated methicillin-resistant Staphylococcus aureus: a role for Panton–Valentine leukocidin? Infect. Immun.77(5), 2159–2167 (2009).
   PubMed Web of Science ®Google Scholar
• Bae IG, Tonthat GT, Fowler VG Jr. Presence of genes encoding the Panton–Valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J. Clin. Microbiol.10(2), 1643–1649 (2009).
   Google Scholar
• Diep BA, Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol.16(8), 361–369 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang K, McClure JA, Elsayed S, Tan J, ConlyJM. Coexistence of Panton–Valentine leukocidin-positive and -negative community-associated methicillin-resistant Staphylococcus aureus USA400 sibling strains in a large Canadian health-care region. J. Infect. Dis.197, 195–204 (2008).
   PubMed Web of Science ®Google Scholar
• Li M, Diep BA, Villaruz AE et al. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc. Natl Acad. Sci. USA106(14), 5883–5888 (2009).
   PubMed Web of Science ®Google Scholar
• Wang R, Braughton KR, Kretschmer D et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med.13, 1510–1514 (2008).
   Web of Science ®Google Scholar
• Novick RP, Ross HF, Projan SJ, Kornblum J, Kreiswirth B, Moghazeh S. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. EMBO J.12, 3967–3975 (1993).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Toltzis P, Chu J et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001–2003. Pediatr. Infect. Dis. J.25(4), 343–348 (2006).
   PubMed Web of Science ®Google Scholar
• Healy CM, Hulten KG, Palazzi DL, Campbell JR, Baker CJ. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin. Infect. Dis.39(10), 1460–1466 (2004).
   PubMed Web of Science ®Google Scholar
• CDC. Community-associated methicillin-resistant Staphylococcus aureus infection among healthy newborns – Chicago and Los Angeles County, 2004. MMWR Morb. Mortal. Wkly Rep.55(12), 329–332 (2006).
   PubMedGoogle Scholar
• CDC. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus – Minnesota and North Dakota, 1997–1999. MMWR Morb. Mortal. Wkly Rep.55(12), 329–332 (2006).
   PubMedGoogle Scholar
• Andrews WW, Schelonka R, Waites K, Stamm A, Cliver SP, Moser S. Genital tract methicillin-resistant Staphylococcus aureus: risk of vertical transmission in pregnant women. Obstet Gynecol.111(1), 113–118 (2008).
   PubMed Web of Science ®Google Scholar
• Fortunov RM, Hulten KG, Hammerman WA, Mason EO Jr, Kaplan SL. Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates. Pediatrics118(3), 874–881 (2006).
   PubMed Web of Science ®Google Scholar
• Archer GL, Pennell E. Detection of methicillin resistance in staphylococci by using a DNA probe. Antimicrob. Agents Chemother.34, 1720–1724 (1990).
   PubMed Web of Science ®Google Scholar
• Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev.10, 781–791 (1997).
   PubMed Web of Science ®Google Scholar
• Tokue Y, Shoji S, Satoh K, Watanabe A, Motomiya M. Comparison of a polymerase chain reaction assay and a conventional microbiologic method for detection of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.36, 6–9 (1992).
   PubMed Web of Science ®Google Scholar
• Murakami K, Minamide W, Wada K, Nakamura E, Teraoka H, Watanabe S. Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction. J. Clin. Microbiol.29, 2240–2244 (1991).
   PubMed Web of Science ®Google Scholar
• Brown DFJ, Edwards DI, Hawkey PM et al. Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA), J. Antimicrob. Chemother.56(6), 1000–1018 (2005).
   PubMed Web of Science ®Google Scholar
• Nakatomi Y, Sugiyama J. A rapid latex agglutination assay for the detection of penicillin-binding protein 2´. Microbiol. Immunol.42, 739–743 (1998).
   PubMed Web of Science ®Google Scholar
• Cavassini M, Wenger A, Jaton K, Blanc DS, Bille J. Evaluation of MRSA-Screen, a simple anti-PBP 2a slide latex agglutination kit, for the rapid detection of methicillin resistant Staphylococcus aureus. J. Clin. Microbiol.37, 1591–1594 (1999).
   PubMed Web of Science ®Google Scholar
• Bekkaoui F, McNevin JP, Leung CH et al. Rapid detection of the mecA gene in methicillin resistant staphylococci using a colorimetric cycling probe technology. Diagn. Microbiol. Infect. Dis.34, 83–90 (1999).
   PubMed Web of Science ®Google Scholar
• Knapp CC, Ludwig MD, Washington JA. Evaluation of BBL Crystal MRSA ID system. J. Clin. Microbiol.32, 2588–2589 (1994).
   PubMed Web of Science ®Google Scholar
• Kampf G, Lecke C, Cimbal AK, Weist K, Rüden H. Evaluation of the BBL Crystal MRSA ID System for detection of oxacillin resistance in Staphylococcus aureus. J. Clin. Pathol.52(3), 225–227 (1999).
   PubMed Web of Science ®Google Scholar
• Arbique J, Forward K, Haldane D, Davidson R. Comparison of the Velogene Rapid MRSA Identification Assay, Denka MRSA-Screen Assay, and BBL Crystal MRSA ID System for rapid identification of methicillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis.40(1–2), 5–10 (2001).
   PubMed Web of Science ®Google Scholar
• Croes S, Beisser PS, Terporten PH, Neef C, Deurenberg RH, Stobberingh EE. Diminished in vitro antibacterial activity of oxacillin against clinical isolates of borderline oxacillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. (2009) (Epub ahead of print).
   Google Scholar
• Hirano L, Bayer AS. β-lactam–β-lactamase-inhibitor combinations are active in experimental endocarditis caused by β-lactamase-producing oxacillin-resistant staphylococci. Antimicrob. Agents Chemother.35, 685–690 (1991).
   PubMed Web of Science ®Google Scholar
• Louie L, Matsumura SO, Choi E, Louie M, Simor AE. Evaluation of three rapid methods for detection of methicillin resistance in Staphylococcus aureus. J. Clin. Microbiol.38(6), 2170–2173 (2000).
   PubMed Web of Science ®Google Scholar
• Paule SM, Hacek DM, Kufner B et al. Performance of the BD GeneOhm methicillin-resistant Staphylococcus aureus test before and during high-volume clinical use. J. Clin. Microbiol.45, 2993–2998 (2007).
   PubMed Web of Science ®Google Scholar
• Grobner S, Kempf VA: Rapid detection of methicillin-resistant staphylococci by real-time PCR directly from positive blood culture bottles. Eur J. Clin. Microbiol. Infect Dis.26, 751–754 (2007).
   PubMed Web of Science ®Google Scholar
• Warren DK, Liao RS, Merz LR, Eveland M, Dunne WM Jr. Detection of methicillin-resistant Staphylococcus aureus directly from nasal swab specimens by a real-time PCR assay. J. Clin. Microbiol.42, 5578–5581 (2004).
   PubMed Web of Science ®Google Scholar
• Lee MC, Rios AM, Aten MF et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr. Infect. Dis. J.2, 123–127 (2004).
   Google Scholar
• Grim SA, Rapp RP, Martin CA et al. Trimethoprim–sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy25, 253–264 (2005).
   PubMed Web of Science ®Google Scholar
• Morinville V, McDonald J. Clostridium difficile-associated diarrhea in 200 Canadian children. Can. J. Gastroenterol.19(8), 497–501 (2005).
   PubMed Web of Science ®Google Scholar
• Volovitz B, Shkap R, Amir J, Calderon S, Varsano I, Nussinovitch M. Absence of tooth staining with doxycycline treatment in young children. Clin. Pediatr.46(2), 121–126 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas MP, Steele RW. Monitoring serum vancomycin levels in children. Is it necessary? Pediatr. Infect. Dis. J.17(4), 351–353 (1999).
   Web of Science ®Google Scholar
• Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother.52(1), 192–197 (2008).
   PubMed Web of Science ®Google Scholar
• Cruciani M, Gattid G, Lazzarinia L et al. Penetration of vancomycin into human lung tissue. J. Antimicrob. Chemother.38, 865–869 (1996).
   PubMed Web of Science ®Google Scholar
• Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis.199(5), 619–624 (2009).
   PubMed Web of Science ®Google Scholar
• Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect.12(Suppl. 1), 16–23 (2006).
   PubMed Web of Science ®Google Scholar
• Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006. Clin. Infect. Dis.46(5), 668–674 (2008).
   PubMed Web of Science ®Google Scholar
• Sieradzki K, Pinho MG, Tomasz A. Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus. J. Biol. Chem.274, 18942–18946 (1999).
   PubMed Web of Science ®Google Scholar
• Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest.111, 1265–1273 (2003).
   PubMed Web of Science ®Google Scholar
• Weigel LM, Clewell DB, Gill SR et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science302(31), 1569–1571 (2003).
   PubMed Web of Science ®Google Scholar
• Cui L, Iwamoto A, Lian JQ et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother.50(2), 428–438 (2006).
   PubMed Web of Science ®Google Scholar
• Sancak B, Ercis S, Menemenlioglu D et al. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J. Antimicrob. Chemother.56, 519–523 (2005).
   PubMed Web of Science ®Google Scholar
• Batts DH. Linezolid – a new option for treating gram-positive infections. Oncology14, 23–29 (2000).
   PubMed Web of Science ®Google Scholar
• Gee T, Ellis R, Marshall G, Andrews J, Ashby, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother.45, 1843–1846 (2001).
   PubMed Web of Science ®Google Scholar
• Welshman IR, Sisson TA, Jungbluth GL, Stalker DJ, Hopkins NK. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm. Drug Dispos.22, 91–97 (2001).
   PubMed Web of Science ®Google Scholar
• Lovering AM, Zhang J, Bannister GC et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J. Antimicrob. Chemother.50, 73–77 (2002).
   PubMed Web of Science ®Google Scholar
• Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid penetration into osteo-articular tissues. J. Antimicrob. Chemother.50, 747–750 (2002).
   PubMed Web of Science ®Google Scholar
• Kutscha-Lissberg F, Hebler U, Muhr G, Köller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant Staphylococci. Antimicrob. Agents Chemother.47(12), 3964–3966 (2003).
   PubMed Web of Science ®Google Scholar
• Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R. Intrapulmonary penetration of linezolid. J. Antimicrob. Chemother.51, 1431–1434 (2003).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis.34, 1481–1490 (2002).
   PubMed Web of Science ®Google Scholar
• Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents.26(6), 442–448 (2005).
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Patterson L, Edwards KM et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatr. Infect. Dis. J.20(5), 488–494 (2001).
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Deville JG, Yogev R et al. Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr. Infect. Dis. J.22(8), 677–686 (2003).
   PubMed Web of Science ®Google Scholar
• Chen CJ, Chiu CH, Lin TY, Lee ZL, Yang WE, Huang YC. Experience with linezolid therapy in children with osteoarticular infections. Pediatr. Infect. Dis. J.26(11), 985–988 (2007).
   PubMed Web of Science ®Google Scholar
• Muñoz P, Rodríguez-Creixéms M, Moreno M, Marín M, Ramallo V, Bouza E; GAME Study Group. Linezolid therapy for infective endocarditis. Clin. Microbiol. Infect.13(2), 211–215 (2007).
   PubMed Web of Science ®Google Scholar
• Sung TJ, Kim HM, Kim MJ. Methicillin-resistant Staphylococcus aureus endocarditis in an extremely low-birth-weight infant treated with linezolid. Clin. Pediatr.47(5), 504–506 (2008).
   PubMed Web of Science ®Google Scholar
• Gerson SL, Kaplan SL, Bruss JB et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother.46, 2723–2726 (2002).
   PubMed Web of Science ®Google Scholar
• Senneville E, Legout L, Valette M et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case–control study. J. Antimicrob. Chemother.54, 798–802 (2004).
   PubMed Web of Science ®Google Scholar
• Tan TQ. Update on the use of linezolid: a pediatric perspective. Pediatr. Infect. Dis. J.23, 955–956 (2004).
   PubMed Web of Science ®Google Scholar
• Saiman L, Goldfarb J, Kaplan SA et al. Safety and tolerability of linezolid in children. Pediatr. Infect. Dis. J.22, S193–S200 (2003).
   PubMed Web of Science ®Google Scholar
• Thai XC, Bruno-Murtha LA. Bell’s palsy associated with linezolid therapy: case report and review of neuropathic adverse events. Pharmacotherapy26(8), 1183–1189 (2006).
   PubMed Web of Science ®Google Scholar
• Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother.47, 2538–2544 (2003).
   PubMed Web of Science ®Google Scholar
• Carpernter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis.38, 994–1000 (2004).
   PubMed Web of Science ®Google Scholar
• Cilli F, Aydemir S, Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. J. Chemother.18(1), 27–32 (2006).
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. The daptomycin 98–01 and 99–01 investigators. Clin. Infect. Dis.38, 1673–1681 (2004).
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr, Boucher HW, Corey GR et al.S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med.355(7), 653–665 (2006).
   PubMed Web of Science ®Google Scholar
• Rehm SJ, Boucher H, Levine D et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J. Antimicrob. Chemother.62(6), 1413–1421 (2008).
   PubMed Web of Science ®Google Scholar
• Lalani T, Boucher HW, Cosgrove SE et al.; S. aureus Endocarditis and Bacteraemia Study Group. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother.61(1), 177–182 (2008).
   PubMed Web of Science ®Google Scholar
• Ardura MI, Mejías A, Katz KS, Revell P, McCracken GH Jr, Sánchez J. Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr. Infect. Dis. J.26(12), 1128–1132 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen-Wolkowiez M, Smith PB, Benjamin DK Jr, Fowler VG Jr, Wade KC. Daptomycin use in infants: report of two cases with peak and trough drug concentrations. J. Perinatol.28(3), 233–234 (2008).
   PubMed Web of Science ®Google Scholar
• Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis.191(12), 2149–2152 (2005).
   PubMed Web of Science ®Google Scholar
• Pertel PE, Bernardo P, Fogarty C et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin. Infect. Dis.46(8), 1152–1156 (2008).
   PubMed Web of Science ®Google Scholar
• Stamatakis MK, Richards JG. Interaction between quinupristin/dalfopristin and cyclosporine. Ann Pharmacother.31(5), 576–578 (1997).
   PubMed Web of Science ®Google Scholar
• Florescu M, Beuran R, Dimov A et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J. Antimicrob. Chemother.62, si17–si17 (2008)
   Google Scholar
• Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J. Antimicrob. Chemother.64(2), 364–369 (2009).
   PubMed Web of Science ®Google Scholar
• Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob. Agents Chemother.52(1), 37–44 (2008).
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis.46(5), 647–655 (2008).
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Graham DR, Wilson SE et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin. Infect. Dis.46(11), 1683–1693 (2008).
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis.36, 1433–1437 (2003).
   PubMed Web of Science ®Google Scholar
• Lehrer RI. Primate defensins. Nat. Rev. Microbiol.2(9), 727–738 (2004).
   PubMed Web of Science ®Google Scholar
• Yangagisawa C, Hanaki H, Natae T, Sunakawa K. Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin. J. Infect. Chemother.13, 368–372 (2007).
   PubMedGoogle Scholar
• Schaad UB. Syndromes caused by staphylococcal toxins (in German). Schweiz Rundsch Med Prax74(43), 1175–1179 (1985).
   PubMedGoogle Scholar
• Shinefield H, Black S, Fattom A. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med.346(7), 491–496 (2002).
   PubMed Web of Science ®Google Scholar